Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$24.85 +2.1%	$26.31	$14.80 ▼ $40.47	$1.89B	0.87	1.01 million shs	669,878 shs
HRMY Harmony Biosciences	$34.19	$34.17	$26.47 ▼ $41.61	$1.97B	0.84	666,956 shs	413,410 shs
IRON Disc Medicine	$58.03 +1.7%	$54.78	$30.82 ▼ $68.73	$2.01B	0.77	405,642 shs	274,630 shs
PGEN Precigen	$1.78 -5.3%	$1.60	$0.65 ▼ $2.17	$525.42M	1.87	2.00 million shs	1.90 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-3.72%	-8.77%	-6.20%	+2.57%	-21.60%
HRMY Harmony Biosciences	-1.38%	-2.81%	+4.40%	+0.41%	+1.91%
IRON Disc Medicine	-3.27%	-4.50%	+7.74%	+29.00%	+38.28%
PGEN Precigen	+2.73%	+9.94%	+10.59%	+41.35%	+59.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	1.6971 of 5 stars	3.5	2.0	0.0	1.9	0.8	0.0
HRMY Harmony Biosciences	4.6977 of 5 stars	4.5	1.0	0.0	3.2	3.3	4.4
IRON Disc Medicine	3.3478 of 5 stars	4.5	3.0	0.0	2.3	2.5	0.0
PGEN Precigen	3.9917 of 5 stars	3.5	1.0	4.7	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.08	Buy	$55.30	122.54% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.00	49.17% Upside
IRON Disc Medicine	3.08	Buy	$95.73	64.96% Upside
PGEN Precigen	3.00	Buy	$6.00	237.08% Upside

Current Analyst Ratings Breakdown

Latest PGEN, IRON, HRMY, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$48.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$33.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$1.14M	1,661.46	N/A	N/A	$9.63 per share	2.58
HRMY Harmony Biosciences	$714.73M	2.75	$2.90 per share	11.77	$13.44 per share	2.54
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
PGEN Precigen	$4.20M	125.07	N/A	N/A	$0.13 per share	13.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$3.10	11.03	10.99	0.51	23.44%	26.34%	17.71%	N/A
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	N/A
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)

Latest PGEN, IRON, HRMY, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
8/13/2025	Q2 2025	PGEN Precigen	-$0.14	N/A	N/A	N/A	$0.67 million	N/A
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	$0.68	-$0.10	$0.68	$204.37 million	$200.49 million
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	30.97	30.97
HRMY Harmony Biosciences	0.20	3.84	3.63
IRON Disc Medicine	0.04	37.65	37.65
PGEN Precigen	N/A	3.53	3.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
HRMY Harmony Biosciences	86.23%
IRON Disc Medicine	83.70%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	7.40%
HRMY Harmony Biosciences	23.60%
IRON Disc Medicine	4.24%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.22 million	70.58 million	Optionable
HRMY Harmony Biosciences	200	57.53 million	43.87 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable

PGEN, IRON, HRMY, and CGON Headlines

Recent News About These Companies

Traders Buy High Volume of Call Options on Precigen (NASDAQ:PGEN)

August 7 at 11:05 AM | marketbeat.com

Precigen (PGEN) Expected to Announce Quarterly Earnings on Wednesday

August 6 at 4:54 AM | marketbeat.com

Precigen Target of Unusually Large Options Trading (NASDAQ:PGEN)

August 1, 2025 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Sees Unusually-High Trading Volume - Still a Buy?

July 31, 2025 | marketbeat.com

Traders Buy High Volume of Precigen Put Options (NASDAQ:PGEN)

July 31, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Trading 10.9% Higher - Here's What Happened

July 24, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Shares Cross Below Two Hundred Day Moving Average - What's Next?

July 23, 2025 | marketbeat.com

HC Wainwright Estimates Precigen's Q1 Earnings (NASDAQ:PGEN)

July 15, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Stock Price Up 7.9% - Should You Buy?

July 14, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Upgraded at Wall Street Zen

July 12, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Sees Unusually-High Trading Volume - Should You Buy?

July 9, 2025 | marketbeat.com

Iridian Asset Management LLC CT Sells 656,113 Shares of Precigen, Inc. (NASDAQ:PGEN)

July 9, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Shares Up 6.6% - Time to Buy?

July 8, 2025 | marketbeat.com

Precigen: August Is Pivotal For This Biotech Innovator

July 7, 2025 | seekingalpha.com

Precigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Precigen Announces Key Approvals at Annual Meeting

July 2, 2025 | theglobeandmail.com

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions

June 12, 2025 | finance.yahoo.com

J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)

May 20, 2025 | theglobeandmail.com

Precigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 17, 2025 | finanznachrichten.de

Cantor Fitzgerald maintains Overweight on Precigen stock

May 17, 2025 | uk.investing.com

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?
By Jordan Chussler | July 21, 2025
View Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?
A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock
By Gabriel Osorio-Mazilli | August 5, 2025
View A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock

PGEN, IRON, HRMY, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$24.85 +0.50 (+2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$24.84 -0.02 (-0.06%)

As of 05:05 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Harmony Biosciences NASDAQ:HRMY

$34.19 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$34.18 0.00 (-0.01%)

As of 04:20 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Disc Medicine NASDAQ:IRON

$58.03 +0.96 (+1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$58.02 -0.01 (-0.02%)

As of 04:58 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Precigen NASDAQ:PGEN

$1.78 -0.10 (-5.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.81 +0.03 (+1.91%)

As of 05:09 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time